Key result
One-time CTX310 CRISPR editing safely sustains reductions in ANGPTL3 and atherogenic lipids at 1 year.
Why the study?
Does one-time CRISPR-Cas9 gene editing with CTX310 safely reduce ANGPTL3 and atherogenic lipids?
Does one-time CRISPR-Cas9 gene editing with CTX310 safely reduce ANGPTL3 and atherogenic lipids?
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“What is compelling about this update is that the reductions in ANGPTL3, triglycerides, and LDL from a single infusion have persisted out to one-year, suggesting a sustained biological effect.”
“Building upon the initial data presented in November 2025, the durability of the lipid-lowering effect was impressive. It is encouraging that there were no serious safety events related to CTX310 in the trial and in the year following treatment. We look forward to continuing to investigate this therapy in a larger number of patients.”
“For the first time, we've shown that a single-course in vivo CRISPR treatment can safely and durably lower ANGPTL3, leading to clinically meaningful reductions in triglycerides and LDL. These data provide strong support for continued advancement of CTX310 and our broader cardiovascular gene-editing portfolio.”
One-time CRISPR-Cas9 gene editing with CTX310 demonstrates early safety and sustained efficacy in reducing atherogenic lipids at 1 year.
In a phase 1a trial, one-time CRISPR-Cas9 gene editing with CTX310 was associated with no treatment-related dose-limiting toxic effects and with sustained reductions in ANGPTL3 and atherogenic lipids at 1 year.
No takes yet. Share an insight, caveat, or question.
Laffin et al. (2026) studied this question. One-time CRISPR-Cas9 gene editing with CTX310 resulted in no treatment-related dose-limiting toxic effects and sustained reductions in ANGPTL3 and atherogenic lipids at 1 year.
Synapse has enriched 10 related papers. Consider them for comparative context: